Founded in 2014, MaaT Pharma is pushing two therapies through clinical trials that are designed improve survival for patients with blood cancers and other diseases. Despite high-profile hiccups, the field of microbiome therapy remains attractive to investors.
Owkin, a startup building a decentralized health research platform, rounded out its series A round with another $18 million in funding. It uses federated learning to allow researchers to collaborate on AI models while keeping data onsite.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.